Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

OBJECTIVE: Inaccessibility of the inflammation compartmentalized to the central nervous system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in progressive multiple sclerosis (MS). The double blind combination of Rituximab by IntraVenous and IntraThecAl injection versus plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Komori, Mika, Lin, Yen Chih, Cortese, Irene, Blake, Andrew, Ohayon, Joan, Cherup, Jamie, Maric, Dragan, Kosa, Peter, Wu, Tianxia, Bielekova, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774261/
https://www.ncbi.nlm.nih.gov/pubmed/27042677
http://dx.doi.org/10.1002/acn3.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774261/
https://www.ncbi.nlm.nih.gov/pubmed/27042677
http://dx.doi.org/10.1002/acn3.293

Ejemplares similares